Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and biopharmaceutical company Pfizer Inc (NYSE:PFE) on Tuesday announced positive data from a Phase 2 study of their Lyme disease vaccine candidate, VLA15.
The study evaluated the immune response and safety profile after a second booster dose.
Results showed a strong immune response and favourable safety profile in all age groups. Seroconversion rates were high, indicating effective protection against Lyme disease.
VLA15 is currently in Phase 3 clinical trials and could potentially be approved in 2026.
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine
Scancell reports promising SCOPE trial data for SCIB1 in advanced melanoma
Transgene teams up with ProBioGen for individualised cancer vaccines
Bio-Works Technologies AB secures LOI for vaccine manufacturing product
LakeShore Biopharma's Phase III YSJA Rabies Vaccine clinical trial receives Chinese NMPA approval